According to the lawsuit, defendants made false and/or misleading statements. Specifically, defendants created the false impression that:
- bluebird could obtain Federal Drug Administration (“FDA”) approval for lovo-cel, gene therapy for sickle cell patients, without any black box warnings for haematological malignancies;
- bluebird would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen bluebird’s financial position for the lovo-cel launch;
- as a result, bluebird had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and
- therefore, bluebird’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
